Chromacity Announces Appointment of New Chairman.
Chromacity Ltd. the leading designer and supplier of ultrafast lasers, announces the appointment of Dr. Andrew McNeill as Chairman, with effect from 1st November 2017. He succeeds Kenneth Fraser, who has stepped down after eighteen months.
Andrew was previously the CEO of Fixed Phage, a role he has held since 2015. Prior to that he was CSO for the orthopaedic biotech company Taragenyx and dermatology company Ambicare Health. He is an entrepreneurial and driven business leader with a track record of commercialising innovative new technologies.
Kevin Grainger, Director of Chromacity commented:
“I am delighted that Andrew has joined the board as chairman at this time. His experience in developing and licensing new technologies will add significant strength to the board.”
“I would also like to take this opportunity to thank Ken for his significant contribution to the Company over the last 18 months. A period, which has seen significant achievements for the Company.”
Commenting on the appointment, Andrew McNeill said:
“I am looking forward to working with the team at Chromacity as they have developed some truly exciting and innovative new products which will allow them to address significant new markets. It is a particularly exciting time for the Company.”
Chromacity, a spin-out from the Ultrafast Optics Group at Heriot-Watt University, design and manufacture a range of ultra-short pulse laser systems. Chromacity has brought to market a range of lasers tailored to the specific requirements of life scientists and spectroscopists by providing a unique combination of power, wavelength coverage and value for money.